Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Article

Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of β-tubulin (Asp26Glu) and less stable microtubules

Malathi Hari, Frank Loganzo, Tami Annable, Xingzhi Tan, Sylvia Musto, Daniel B. Morilla, James H. Nettles, James P. Snyder and Lee M. Greenberger
Malathi Hari
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frank Loganzo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tami Annable
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xingzhi Tan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sylvia Musto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel B. Morilla
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James H. Nettles
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James P. Snyder
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lee M. Greenberger
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1535-7163.MCT-05-0190 Published February 2006
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Additional Files
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Chemical structure of paclitaxel, docetaxel, and MAC-321.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    KB-15-PTX/099 cells are resistant to paclitaxel but retain sensitivity to HTI-286 in vivo. KB-3-1 (open symbols/dotted lines) or KB-15-PTX/099 (closed symbols/solid lines) tumor cells were implanted s.c. into athymic mice. Animals bearing established tumors were treated i.v. with saline (diamonds), 1.25 mg/kg HTI-286 (squares), or 60 mg/kg paclitaxel (triangles). Vehicle and drugs were administered weekly for three cycles. Points, mean of tumor size (mg) at each time point; bars, SD. *, P < 0.01, significant difference between treatments versus vehicle is indicated at the end of the treatment periods.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    Analysis of P-glycoprotein levels and accumulation of paclitaxel in KB-3-1 parental and resistant cell lines. A, the indicated cell lines were analyzed for levels of P-glycoprotein (P-gp). Protein levels were determined by SDS-PAGE/immunoblot analyses. Positive control cell lines are included for P-glycoprotein expression (KB-15-PTX and KB-8.5). B, the cell lines were analyzed for mRNA expression by quantitative reverse transcription-PCR, with relative ratio of P-glycoprotein/actin set to 1 for KB-3-1 cells. C, the indicated cell lines were incubated for 2 h with [14C]paclitaxel ([14C]PTX) and levels of radioactive drug remaining in cells quantified by liquid scintillation counting. Representative experiment. Columns, percentage of drug remaining in resistant cells compared with parental cells (KB-3-1) set at 100%; bars, SD. *, P < 0.01, significant difference from KB-3-1.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    Dependence of KB-15-PTX/099 cells on microtubule-stabilizing agents. KB-15-PTX/099 cells were grown in the indicated tubulin agents, and growth was measured after 3 d. One hundred percent growth of untreated cells (dotted line). Microtubule-stabilizing agents (closed symbols). Microtubule-destabilizing agents (open symbols).

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    Comparison of microtubule stability in parental and paclitaxel resistant cells. A, cells were grown in the presence (white columns) or absence (black columns) of 15 nmol/L paclitaxel, and the amount of tubulin in microtubules was measured as described in Materials and Methods. The intensity of the tubulin band in the immunoblot was quantified. Columns, average of three measurements; bars, SD. *, P < 0.01, significant difference between indicated cell line and treatments versus KB-3-1 in the absence of paclitaxel. B, cells were grown in the absence of paclitaxel, and the amount of acetylated tubulin was measured by immunoblotting with an acetylated tubulin–specific antibody. Columns, average percentage of acetylated-tubulin from three experiments normalized to actin and KB-3-1 set to 100%; bars, SE. *, P < 0.05.

  • Figure 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6.

    Paclitaxel (“T-Taxol”) docked and optimized in β-tubulin. Model (from ref. 39) shows several protein side chains interacting with the bound ligand.

  • Figure 7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 7.

    Model of paclitaxel and docetaxel in wild-type and mutant tubulin. Amber94/MOE energy optimized models of paclitaxel (magenta) and docetaxel (teal) in the binding site of wild-type and mutant β-tubulin; protein carbons (white). A, in the Asp26 wild type, the protein atoms of each model are almost completely superimposable, with only a small displacement of His227 (<0.1Å). The hydrophobic C-3′ NHR end group of each ligand packs against the Van der Waal surfaces of both the Asp26 CH2 (heavy atom distances, 3.5 Å) and the Val23 side chains. The OtBu of docetaxel allows positioning of its C-3′ N-H within hydrogen bonding distance (2.0 Å) of the Asp26 carboxylate, whereas the additional bulk of the paclitaxel phenyl keeps its N-H ≥2.8Å away from the carboxylate. The corresponding reduction in noncovalent attraction may account for the lower activity of paclitaxel in wild-type systems. B, the Glu26 mutants were derived from the wild-type models and potential rotamer positions analyzed (only paclitaxel shown). Three possible rotamer states (R1–R3) were identified for each ligand complex [cf. text and Table S1 (available at http://mct.aacrjournals.org)] to provide starting structures for further force field optimization.

  • Figure 8.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 8.

    Overlay comparisons of wild-type versus mutant complexes of paclitaxel and docetaxel (Glu26/rotamer R2). Protein carbons (white). A, docetaxel: wild type (teal), Glu26 (orange). Optimization of the glutamate/R2 complex results in packing of the OtBu group between the tubulin residues Val23 (data not shown; cf. Fig. 7) and His227. The orange ligand shows an AspCO2-HN hydrogen bond while maintaining the locations of the baccatin core and the attached C-2 side chain. B, paclitaxel: wild type (magenta), Glu26 (yellow). Glu26 (shown as Van der Waal surface) causes extensive rearrangement of the paclitaxel complex. The drug experiences a 1.8 Å root mean square displacement of the C-2 heavy atom positions relative to the wild-type complex and moves partway out of the binding pocket.

Tables

  • Figures
  • Additional Files
  • Table 1.

    Profile of KB-3-1 cells selected for resistance to paclitaxel

    CompoundIC50 (nmol/L)*, KB-3-1IC50 (nmol/L), KB-15-PTX/099Relative resistance†IC50 (nmol/L), KB-15-PTXRelative resistance
    Microtubule-polymerizing agents
        Paclitaxel2.4 ± 0.444.2 ± 16.918.271.2 ± 17.629.3
        Docetaxel0.84 ± 0.464.1 ± 1.84.98.1 ± 1.99.7
        MAC-3210.57 ± 0.062.3 ± 0.23.91.1 ± 0.62.0
        Epothilone B0.61 ± 0.032.1 ± 0.13.40.84 ± 0.011.4
    Microtubule-depolymerizing agents
        Vinblastine0.82 ± 0.270.21 ± 0.040.33.0 ± 1.63.7
        HTI-2860.61 ± 0.110.20 ± 0.040.30.52 ± 0.080.8
        Dolastatin-100.041 ± 0.0100.012 ± 0.0040.3NDND
    DNA-damaging agents
        Mitoxantrone7.7 ± 2.023.6 ± 4.13.113.5 ± 3.11.8
        Adriamycin56.5 ± 41.376.0 ± 20.01.4NDND
        Bisantrene68.9 ± 45.257.8 ± 46.50.8764 ± 10711.1
    • Abbreviation: ND, not determined.

    • ↵* Mean IC50 (nmol/L) ± SD from two to six independent determinations.

    • ↵† Relative resistance = ratio of IC50 of the resistant cell line to IC50 of the parental line.

Additional Files

  • Figures
  • Tables
  • Supplementary Data, Hari et al.

    Files in this Data Supplement:

    • Supplementary Materials - Supplementary Methods, Table S1, and Figure S1
PreviousNext
Back to top
Molecular Cancer Therapeutics: 5 (2)
February 2006
Volume 5, Issue 2
  • Table of Contents
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of β-tubulin (Asp26Glu) and less stable microtubules
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of β-tubulin (Asp26Glu) and less stable microtubules
Malathi Hari, Frank Loganzo, Tami Annable, Xingzhi Tan, Sylvia Musto, Daniel B. Morilla, James H. Nettles, James P. Snyder and Lee M. Greenberger
Mol Cancer Ther February 1 2006 (5) (2) 270-278; DOI: 10.1158/1535-7163.MCT-05-0190

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of β-tubulin (Asp26Glu) and less stable microtubules
Malathi Hari, Frank Loganzo, Tami Annable, Xingzhi Tan, Sylvia Musto, Daniel B. Morilla, James H. Nettles, James P. Snyder and Lee M. Greenberger
Mol Cancer Ther February 1 2006 (5) (2) 270-278; DOI: 10.1158/1535-7163.MCT-05-0190
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Prediction of individual response to platinum/paclitaxel combination using novel marker genes in ovarian cancers
  • Low doses of cisplatin or gemcitabine plus Photofrin/photodynamic therapy: Disjointed cell cycle phase-related activity accounts for synergistic outcome in metastatic non–small cell lung cancer cells (H1299)
  • Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells
Show more Article
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement